Woman using walker in a clinical setting, with text reading “Just because she isn't suffering an attack doesn't mean she isn't suffering”Woman using walker in a clinical setting, with text reading “Just because she isn't suffering an attack doesn't mean she isn't suffering”

Is it time to act? Your NMOSD patients may be revealing new or worsening disease activity like pain, vision changes, or bladder/bowel symptoms or have difficulty with dosing regimens.1,2

If you hear these cries for help, it may be time to intervene.

NMOSD management should include:

Early, accurate diagnosis icon

Evaluating the long-term efficacy of therapy2

Methods of Monitoring

Patient's quality of life icon

Assessing the ongoing impact of the disease1,2

See How Disability Can Accumulate

Shield with a checkmark icon

Treatment decisions that involve more than attack reduction alone3,4

Explore the Evolution of Treatment

SupportExplore NMOSD resources Support for Your Patients

Stay Up to Date Receive the latest information about NMOSD Sign Up Now

NMOSD, neuromyelitis optica spectrum disorder.

  1. Eaneff S, Wang V, Hanger M, et al. Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017;17:116-122.
  2. Paul F, Marignier R, Palace J, et al. International Delphi Consensus on the management of AQP4· lgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. doi: 10.1212/NXl.0000000000200124
  3. Held F, Klein A-K, Berthele A. Drug treatment of neuromyelitis optica spectrum disorders: out with the old, in with the new? Immunotargets Ther. 2021;10:87-101
  4. Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022;387:631-639. doi:10.1056/NEJMra1904655